Patient selection and vitamin E treatment in diabetes mellitus

References

• Factor SM, Minase T, Sonnenblick EH. Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am. Heart J. 99(4), 446–458 (1980).
   PubMed Web of Science ®Google Scholar
• Virtamo J, Rapola JM, Ripatti S et al. Effect of vitamin E and β carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch. Intern. Med. 158(6), 668–675 (1998).
   PubMed Web of Science ®Google Scholar
• de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 357(9250), 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J. Am. Coll. Cardiol. 46(1), 166–172 (2005).
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, LaBree L et al.; VEAPS Research Group. α-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 106(12), 1453–1459 (2002).
   PubMed Web of Science ®Google Scholar
• Nanayakkara PW, van Guldener C, ter Wee PM et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima–media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch. Intern. Med. 167(12), 1262–1270 (2007).
   PubMedGoogle Scholar
• Lee IM, Cook NR, Gaziano JM et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294(1), 56–65 (2005).
   PubMed Web of Science ®Google Scholar
• Sesso HD, Buring JE, Christen WG et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA 300(18), 2123–2133 (2008).
   PubMed Web of Science ®Google Scholar
• Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI–Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 354(9177), 447–455 (1999).
   PubMed Web of Science ®Google Scholar
• Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347(9004), 781–786 (1996).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3), 154–160 (2000).
   PubMed Web of Science ®Google Scholar
• Lonn E, Bosch J, Yusuf S et al.; HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293(11), 1338–1347 (2005).
   PubMed Web of Science ®Google Scholar
• Waters DD, Alderman EL, Hsia J et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 288(19), 2432–2440 (2002).
   PubMed Web of Science ®Google Scholar
• Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356(9237), 1213–1218 (2000).
   PubMed Web of Science ®Google Scholar
• Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 142(1), 37–46 (2005).
   PubMed Web of Science ®Google Scholar
• Berry D, Wathen JK, Newell M. Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality. Clin. Trials 6(1), 28–41 (2009).
   PubMed Web of Science ®Google Scholar
• Gerss J, Köpcke W. The questionable association of vitamin E supplementation and mortality – inconsistent results of different meta-analytic approaches. Cell. Mol. Biol. (Noisy-le-Grand) 55(Suppl.), OL1111–OL1120 (2009).
   PubMed Web of Science ®Google Scholar
• Dotan Y, Pinchuk I, Lichtenberg D, Leshno M. Decision analysis supports the paradigm that indiscriminate supplementation of vitamin E does more harm than good. Arterioscler. Thromb. Vasc. Biol. 29(9), 1304–1309 (2009).
   PubMed Web of Science ®Google Scholar
• Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst. Rev. 3, CD007176 (2012).
   PubMed Web of Science ®Google Scholar
• Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297(8), 842–857 (2007).
   PubMed Web of Science ®Google Scholar
• Yeboah J, McClelland RL, Polonsky TS et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 308(8), 788–795 (2012).
   PubMed Web of Science ®Google Scholar
• Milman U, Blum S, Shapira C et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both Type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler. Thromb. Vasc. Biol. 28(2), 341–347 (2008).
   PubMed Web of Science ®Google Scholar
• Blum S, Vardi M, Brown JB et al. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics 11(5), 675–684 (2010).
   PubMed Web of Science ®Google Scholar
• Vardi M, Blum S, Levy AP. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus – natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. Eur. J. Intern. Med. 23(7), 628–632 (2012).
   PubMed Web of Science ®Google Scholar
• Levy AP, Asleh R, Blum S et al. Haptoglobin: basic and clinical aspects. Antioxid. Redox Signal. 12(2), 293–304 (2010).
   PubMed Web of Science ®Google Scholar
• Asleh R, Marsh S, Shilkrut M et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ. Res. 92(11), 1193–1200 (2003).
   PubMed Web of Science ®Google Scholar
• Goldenstein H, Levy NS, Levy AP. Haptoglobin genotype and its role in determining heme–iron mediated vascular disease. Pharmacol. Res. 66(1), 1–6 (2012).
   PubMed Web of Science ®Google Scholar
• Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin. Chem. 42(10), 1589–1600 (1996).
   PubMed Web of Science ®Google Scholar
• Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW. Hemoglobin. A biologic fenton reagent. J. Biol. Chem. 259(23), 14354–14356 (1984).
   PubMed Web of Science ®Google Scholar
• Rifkind JM, Ramasamy S, Manoharan PT, Nagababu E, Mohanty JG. Redox reactions of hemoglobin. Antioxid. Redox Signal. 6(3), 657–666 (2004).
   PubMed Web of Science ®Google Scholar
• Belcher JD, Beckman JD, Balla G, Balla J, Vercellotti G. Heme degradation and vascular injury. Antioxid. Redox Signal. 12(2), 233–248 (2010).
   PubMed Web of Science ®Google Scholar
• Bamm VV, Tsemakhovich VA, Shaklai M, Shaklai N. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry 43(13), 3899–3906 (2004).
   PubMed Web of Science ®Google Scholar
• Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ. Res. 96(4), 435–441 (2005).
   PubMed Web of Science ®Google Scholar
• Asleh R, Blum S, Kalet-Litman S et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 57(10), 2794–2800 (2008).
   PubMed Web of Science ®Google Scholar
• Asleh R, Miller-Lotan R, Aviram M et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ. Res. 99(12), 1419–1425 (2006).
   PubMed Web of Science ®Google Scholar
• Conway B, Fried L, Orchard T. Hemoglobin and overt nephropathy complications in Type 1 diabetes. Ann. Epidemiol. 18(2), 147–155 (2008).
   PubMed Web of Science ®Google Scholar
• Asleh R, Levy AP. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc. Health Risk Manag. 1(1), 19–28 (2005).
   PubMedGoogle Scholar
• Levy AP, Hochberg I, Jablonski K et al.; Strong Heart Study. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J. Am. Coll. Cardiol. 40(11), 1984–1990 (2002).
   PubMed Web of Science ®Google Scholar
• Suleiman M, Aronson D, Asleh R et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 54(9), 2802–2806 (2005).
   PubMed Web of Science ®Google Scholar
• Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care 26(9), 2628–2631 (2003).
   PubMed Web of Science ®Google Scholar
• Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype: a determinant of cardiovascular complication risk in Type 1 diabetes. Diabetes 57(6), 1702–1706 (2008).
   PubMed Web of Science ®Google Scholar
• Simpson M, Snell-Bergeon JK, Kinney GL et al. Haptoglobin genotype predicts development of coronary artery calcification in a prospective cohort of patients with Type 1 diabetes. Cardiovasc. Diabetol. 10, 99 (2011).
   PubMed Web of Science ®Google Scholar
• Melamed-Frank M, Lache O, Enav BI et al. Structure–function analysis of the antioxidant properties of haptoglobin. Blood 98(13), 3693–3698 (2001).
   PubMed Web of Science ®Google Scholar
• Costacou T, Evans RW, Orchard TJ. High-density lipoprotein cholesterol in diabetes: is higher always better? J. Clin. Lipidol. 5(5), 387–394 (2011).
   PubMed Web of Science ®Google Scholar
• Levy AP, Gerstein HC, Miller-Lotan R et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 27(11), 2767 (2004).
   PubMed Web of Science ®Google Scholar
• Blum S, Milman U, Shapira C et al. Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler. Thromb. Vasc. Biol. 28(3), e18–e20 (2008).
   PubMed Web of Science ®Google Scholar
• Farbstein D, Blum S, Pollak M et al. Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype. Atherosclerosis 219(1), 240–244 (2011).
   PubMed Web of Science ®Google Scholar
• Levy AP, Friedenberg P, Lotan R et al. The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women. Diabetes Care 27(4), 925–930 (2004).
   PubMed Web of Science ®Google Scholar
• Asleh R, Levy AP. Divergent effects of α-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype. Antioxid. Redox Signal. 12(2), 209–217 (2010).
   PubMed Web of Science ®Google Scholar
• Lönn ME, Dennis JM, Stocker R. Actions of ‘antioxidants’ in the protection against atherosclerosis. Free Radic. Biol. Med. 53(4), 863–884 (2012).
   PubMed Web of Science ®Google Scholar
• Fradkin J, Rodgers GP. The economic imperative to conquer diabetes. Diabetes Care 31(3), 624–625 (2008).
   PubMed Web of Science ®Google Scholar